Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1989 Oct;65(768):725–728. doi: 10.1136/pgmj.65.768.725

Chronic active hepatitis: a sixteen year survey at a district general hospital.

A R Tanner 1, A W Dellipiani 1
PMCID: PMC2429844  PMID: 2616397

Abstract

Over a period of 16 years (1971-87) all cases of chronic active hepatitis (CAH) diagnosed following liver biopsy have been reviewed to assess incidence, aetiology, outcome and response to treatment. North Tees District serves a population of 210,000 and 26 cases were identified (20 female) age range 9-73 years (median 56 years). Incidence remained constant at 1:100,000/year. Twenty cases (77%) had an immune aetiology. Other aetiologies were hepatitis B virus (HBV) infection, alpha-1AT deficiency, non-A non-B hepatitis and a complex multisystem disease. The median follow-up period was 50 months. There were 7 deaths, three unrelated to liver disease. Survival analysis gives an 86% 5-year survival and 56% 10-year survival. Twenty four patients were treated with steroids (and 6 additionally with azathioprine); 15 (63%) were steroid responsive and 9 were non-responsive. In five patients steroids were successfully discontinued but in 10 patients severe symptomatic relapse occurred on steroid reduction below 7.5-10 mg/day. Steroid non-responders were not typical CAH, 5 with predominantly a rise in alkaline phosphatase, one multisystem disease and one HBV positive. Steroid discontinuation was only possible in one third of the patients responding. Eighteen subjects (69%) were cirrhotic at initial biopsy; 9 had follow-up biopsies, 6 were unchanged but three had progressed to cirrhosis despite apparent steroid responsiveness.

Full text

PDF
725

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baggenstoss A. H., Soloway R. D., Summerskill W. H., Elveback L. R., Schoenfield L. J. Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution. Hum Pathol. 1972 Jun;3(2):183–198. doi: 10.1016/s0046-8177(72)80072-8. [DOI] [PubMed] [Google Scholar]
  2. Cook G. C., Mulligan R., Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971 Apr;40(158):159–185. doi: 10.1093/oxfordjournals.qjmed.a067264. [DOI] [PubMed] [Google Scholar]
  3. Geubel A. P., Baggenstoss A. H., Summerskill W. H. Responses to treatment can differentiate chronic active liver disease with cholangitic features from the primary biliary cirrhosis syndrome. Gastroenterology. 1976 Sep;71(3):444–449. [PubMed] [Google Scholar]
  4. Hegarty J. E., Nouri Aria K. T., Portmann B., Eddleston A. L., Williams R. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology. 1983 Sep-Oct;3(5):685–689. doi: 10.1002/hep.1840030510. [DOI] [PubMed] [Google Scholar]
  5. Hodges J. R., Millward-Sadler G. H., Wright R. Chronic active hepatitis: the spectrum of disease. Lancet. 1982 Mar 6;1(8271):550–552. doi: 10.1016/s0140-6736(82)92056-6. [DOI] [PubMed] [Google Scholar]
  6. Kirk A. P., Jain S., Pocock S., Thomas H. C., Sherlock S. Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis. Gut. 1980 Jan;21(1):78–83. doi: 10.1136/gut.21.1.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Koretz R. L., Stone O., Gitnick G. L. The long-term course of non-A, non-B post-transfusion hepatitis. Gastroenterology. 1980 Nov;79(5 Pt 1):893–898. [PubMed] [Google Scholar]
  8. Lam K. C., Lai C. L., Trepo C., Wu P. C. Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med. 1981 Feb 12;304(7):380–386. doi: 10.1056/NEJM198102123040702. [DOI] [PubMed] [Google Scholar]
  9. Maddrey W. C., Boitnott J. K. Drug-induced chronic liver disease. Gastroenterology. 1977 Jun;72(6):1348–1353. [PubMed] [Google Scholar]
  10. McFarlane I. G., Hegarty J. E., McSorley C. G., McFarlane B. M., Williams R. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet. 1984 Oct 27;2(8409):954–956. doi: 10.1016/s0140-6736(84)91167-x. [DOI] [PubMed] [Google Scholar]
  11. Murray-Lyon I. M., Stern R. B., Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973 Apr 7;1(7806):735–737. doi: 10.1016/s0140-6736(73)92125-9. [DOI] [PubMed] [Google Scholar]
  12. Schalm S. W., Summerskill W. H., Gitnick G. L., Elveback L. R. Contrasting features and responses to treatment of severe chronic active liver disease with and without hepatitis BS antigen. Gut. 1976 Oct;17(10):781–786. doi: 10.1136/gut.17.10.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shouval D., Levij I. S., Eliakim M. Chronic active hepatitis with cholestatic features. I. A clinical and immunological study. Am J Gastroenterol. 1979 Nov;72(5):542–550. [PubMed] [Google Scholar]
  14. Soloway R. D., Summerskill W. H., Baggenstoss A. H., Geall M. G., Gitnićk G. L., Elveback I. R., Schoenfield L. J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972 Nov;63(5):820–833. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES